CAROLYN ADAMS: Open Payments
NPI 1962824805 · LIVERPOOL, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$743 in 38 payments from 15 companies in 2025. Trend: 2023 $666 · 2024 $717 · 2025 $743
Food & beverage: $743
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $90 |
| Abbott Laboratories | 4 | $83 |
| ABBVIE INC. | 4 | $73 |
| Madrigal Pharmaceuticals | 2 | $67 |
| Lilly USA, LLC | 4 | $66 |
| Novo Nordisk Inc | 4 | $62 |
| GlaxoSmithKline, LLC. | 3 | $51 |
| Astellas Pharma US Inc | 2 | $47 |
| Amgen Inc. | 3 | $46 |
| Merck Sharp & Dohme LLC | 2 | $44 |
Products named: Kerendia, FREESTYLE LIBRE 3, REZDIFFRA, QULIPTA, TRELEGY ELLIPTA, Veozah, Rybelsus, LAGEVRIO.
Industry payments across NY — which companies pay providers there.
